FIELD: medicine, peptides.
SUBSTANCE: invention relates to biologically active compounds representing isolated derivatives of corticotropin-releasing factor. Invention presents non-native peptide of the formula: I-V-L-S-L-D-V-P-I-G-L-L-Q-I-L-L-E-Q-X19-K-X21-X22-X23-X24-X25-X26-Q-A-T-T-N-A-R-I-L-A-R-V (SEQ ID NO: 531) wherein (a) X19 is chosen from the group consisting of D and E; (b) X21 is chosen from the group consisting of A and Q; (c) X22 is chosen from the group consisting of R, E and K; (d) X23 is chosen from the group consisting of A, K and N; (e) X24 is chosen from the group consisting of A, E and L; (f) X25 is chosen from the group consisting of R and K; (g) X26 is chosen from the group consisting of E and Q. Isolated derivatives of corticotropin-releasing factor and nucleic acids encoding thereof are effective agents used in treatment of disorders modulated by corticotropin-releasing factor-2, such as muscular dystrophy.
EFFECT: valuable medicinal properties of agonists.
Title | Year | Author | Number |
---|---|---|---|
AGONISTS OF CORTICOTROPIN-RELEASING FACTOR (CRFR) RECEPTOR AND THEIR USING | 2003 |
|
RU2294333C2 |
CORTICOTROPIN-RELEASING FACTOR RECEPTOR AGONISTS AND USES THEREOF | 2003 |
|
RU2305110C2 |
METHODS FOR IDENTIFYING COMPOUNDS USED FOR REGULATION OF MUSCLE MASS OR FUNCTION WITH APPLYING RECEPTORS OF CORTICOTROPIN RELEASING-FACTOR | 2002 |
|
RU2260805C2 |
UROCORTIN-III, ITS ANALOG (VARIANTS) AND PHARMACEUTICAL COMPOSITION | 2002 |
|
RU2305109C2 |
UROCORTIN PROTEINS AND THEIR USING | 2001 |
|
RU2278871C2 |
DOUBLE TARGETING OF NUCLEOTIDE SEQUENCES MIR-208 AND MIR 499 IN TREATING CARDIAC DISEASES | 2010 |
|
RU2515926C2 |
COMPOSITIONS AND METHODS RELATED TO SOLUBLE G-PROTEIN CONJUGATE RECEPTORS (SGPCR) | 2006 |
|
RU2423378C2 |
IMPROVED ANTIBODIES GDF-8 ANTAGONISTS AND THEIR USE | 2013 |
|
RU2630634C2 |
THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | 2013 |
|
RU2655811C2 |
APPLICATION OF GROWTH HORMONE FRAGMENTS | 2012 |
|
RU2639474C2 |
Authors
Dates
2006-11-10—Published
2003-01-16—Filed